Make your own free website on Tripod.com
GREATER TAMPA CHAPTER
ONCOLOGY NURSING SOCIETY
WRITE O.N.

ONLINE VERSION PAGE 6


Volume 14 Number 1 WINTER, 1997

bus

5 MINUTE EDUCATION


FROM THE PHARMACY

by Patty Geddie, RN OCN, CNS
Walt Disney Memorial Cancer Institute
Greater Orlando ONS member
Guest Contributor

ABELCET (Amphotericin B Lipid Complex, Injection)

ABELCET consists of Amiphotericin B complexed with two phospholipids in a 1:1 drug - to -lipid molar ratio.
Indication: for the treatment of aspergillosis in patients who are refractory to or intolerant of conventional Amphotericin B therapy.
Contraindications: Hypersensitivity to Amphotericin B
Adverse Effects: chills, fever, sepsis, organ failure, headache, infection, pain, hypotension, nausea, vomiting, diarrhea, pancytopenia, hypokalemia, increased serum creatinine, dyspnea, rash, kidney failure, anaphylaxis.
Dosage and Administration: 5.0 mg/kg as a single infusion, rate of 2.5 mg/kg/hr. If exceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours. Do not Dilute with Saline, other drugs or electrolytes! Flush IV line with 5% Dextrose. Do not use an inline filter less than 5 microns!


JOURNAL CLUB


JOURNAL of INTRAVENOUS NURSING
May / June 1996
Number 3, Volume 19

"Amphotericin B in 20% Lipid Emulsion"
by Kimberly A. Ryan, CRNI, BA

This article examines administration protocols for AmphoB Lipid Complex. Traditionally, AmphoB has been mixed in D5W and infused over 4 -6 hours with pre and or post hydration and medications for side effect control. The new form is mixed in 20% Lipid Emulsion hoping for decreased side effects and shorter infusion time. The author was administering the drug in the patient's homes. In her situation, there was no pre or post hydration, no pre-meds, and the drug was infused over 2 hours.
She did not evaluate the patient response in this article; but referenced an article by Moreau, P.; Milipied N.; & Fayerette N. in the Journal of Antimicrobial Chemotherapy, 1992, that claimed, "Reduced renal toxicity and improved clinical tolerance of AmphoB mixed with Intralipid compared with conventional AmphoB in Neutropenic patients."


AJN May 1996 Vol. 96 No. 5

"When A Loved One Is Dying: Families Talk About Nursing Care"
by Marykay Czerwiec, RN, BSN

The author was a co-investigator in a research study at two major hospitals in Chicago interviewing the next - of - kin of 30 people who had died 3 - 5 months before. The number one factor in family satisfaction was perceiving the staff to having a caring attitude toward the patien and family and to be acting on the patient's behalf.
Highest dissatisfaction was related to not being kept informed about the patient's condition, not being honest, and lack of this caring attitude. Nurses had the least amount of negative comments than any other health care team members! The subjects noted both the nurse's actions and attitudes. "Patient", "caring", and "compassionate" were all used to describe the nurses. and they were given high marks for keeping the patient comfortable and clean. Another important factor was just the nurse's presence - making the family feel that she/he would make time for them. The author gave some suggestions for being more effective, such as, sit down when talking with the family, showing interest in hearing about the patient, and actively listening. Also, don't give false hope - families are happy just to have a nurse present. She also suggested using the Nursing Process to individualize how you deal with each family.


PREVIOUS PAGE
IN THIS ISSUE (MENU)
NEXT PAGE